Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Mucosal-associated invariant T (MAIT) cells are anti-bacterial effector T cells that react to pyrimidines derived from bacte-rial riboflavin synthesis. We show here that a major challenge in MAIT cell research is that the commonly used MAIT ago-nist precursor, 5-amino-6-D-ribitylaminouracil (5-A-RU), is labile to auto-oxidation resulting in loss of biological activity. To overcome this, we report the synthesis of a 5-A-RU prodrug generated by modification of the 5-amino group with a cleava-ble valine-citrulline-p-aminobenzyl carbamate. The compound is stable in prodrug form, with the biologically active MAIT agonist precursor only released after enzymatic cleavage. Analysis of the prodrug in vitro and in vivo showed an enhanced MAIT cell activation profile compared to 5-A-RU, which was associated with preferential loading within recycling endo-somes, a route used by some natural agonists. This prodrug design therefore overcomes the difficulties associated with 5-A-RU in biological studies, and provides an opportunity to explore different presentation pathways.

Original publication

DOI

10.1021/acschembio.9b00902

Type

Journal article

Journal

ACS Chem Biol

Publication Date

07/01/2020